Discover Takeda Oncology's decades of leadership in oncology. Explore their approach, latest news, pipeline, and innovative therapies.

Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology

# Decades of Leadership in Oncology



Discover Takeda's latest data in oncology with Phase 3 clinical data, real-world evidence, and patient and HCP surveys at the ASCO 2025 Annual Meeting.

Phase 3 Clinical Data from Takeda’s Oncology Pipeline and Portfolio to be Presented at 2025 ASCO Annual Meeting

* **Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo**
* **All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes**
* **Rusfertide was generally well tolerated; no new safety findings were observed in the study**

**NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025** – Protagonist Therapeutics, Inc. (“Protagonist”) ([NASDAQ:PTGX](https://www.protagonist-inc.com/)) and Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/overview/)) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration (FDA).

Key findings from the study include:

* The primary endpoint of the study was met, with a significantly higher proportion of clinical responders1 among rusfertide-treated patients with PV (77%) compared to those who received placebo (33%) during weeks 20-32; p<0.0001. The primary endpoint of the study was the proportion of patients achieving a response, which was defined as the absence of phlebotomy eligibility.
* The first key secondary endpoint, which is the pre-specified primary endpoint for European Union (EU) regulators, was also met, with a mean of 0.5 phlebotomies per patient in the rusfertide arm compared to 1.8 phlebotomies per patient in the placebo arm during weeks 0-32; p<0.0001.
* The other three pre-specified key secondary endpoints, namely hematocrit control2 and patient-reported outcomes using PROMIS Fatigue SF-8a3 and MFSAF TSS-74, were also achieved with statistical significance.
* Rusfertide was generally well tolerated in the Phase 3 VERIFY trial, and safety was in line with previous rusfertide clinical studies. No new safety findings were observed in the study. The majority of adverse events were grade 1-2 injection site reactions and all serious adverse events reported were deemed to be not drug related. There was no evidence of an increased risk of cancer in rusfertide-treated patients compared to those on placebo.

“The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class erythrocytosis-specific agent to address unmet medical needs in patients with PV who are unable to achieve adequate hematocrit control despite standard of care treatments,” said Arturo Molina, M.D., M.S., Chief Medical Officer of Protagonist. “We plan to submit additional details of these promising results for presentation at upcoming medical conferences in 2025. We are immensely grateful to the patients, study staff and principal investigators who made the VERIFY study possible.”

Patients with PV are at increased risk for life-threatening cardiovascular and thrombotic events. Many patients with PV require regular phlebotomy, a process of removing blood to manage elevated hematocrit levels caused by an excess of red blood cells, as well as treatment with cytoreductive therapies. Phlebotomy can be burdensome and exacerbate symptoms, including severe fatigue, visual disturbances and iron deficiency, which impact patients’ quality of life. The reduction of hematocrit below 45% is a primary treatment goal for patients with PV as recommended by current treatment guidelines.

“We are encouraged by these results and excited about the potential of rusfertide to help patients living with PV. These patients may experience a high treatment burden, and severe symptoms can impact their quality of life,” said Andy Plump, M.D., Ph.D., President of R\&D at Takeda. “We are deeply committed to bringing additional treatment options to those living with blood cancers, including myeloid cancers such as PV.”

“The totality of impressive clinical data to date shows that rusfertide has the potential for meaningful positive impact on the lives of patients with PV,” said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. “We look forward to working with our partner, Takeda, to submit our findings to the regulatory agencies. Today’s study results also mark a critical inflection point in Protagonist’s decade long journey in the hepcidin program and further validates our platform and expertise in innovating highly differentiated peptide-based medicines to fulfill unmet medical needs.”

Under the license and collaboration agreement between Protagonist and Takeda, Protagonist earns a $25 million milestone payment following these positive results. The milestone is payable following completion of the VERIFY clinical study report.

The impact on Takeda’s financial results for the fiscal year ending March 31, 2025 (FY2024), following the study results, is immaterial.

Protagonist will host a conference call and webcast, for which details can be found below.

## Protagonist Investor Conference Call and Webcast Details

The dial-in numbers for Protagonist’s investor update on Monday, March 3rd at 8:30 am ET are:

* US-based Investors: 1-877-300-8521
* International Investors: 1-412-317-6026
* Conference Call ID: 1793905

The webcast link for the event can be found here: <https://viavid.webcasts.com/starthere.jsp?ei=1708360&tp_key=94f2832555>

A replay of the presentation will be available on the Protagonist Investor Relations Events and Presentations webpage following the event.

## About VERIFY

The Phase 3 VERIFY trial (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The trial is evaluating the efficacy and safety of once-weekly, subcutaneously self-administered rusfertide in patients with uncontrolled hematocrit who are phlebotomy dependent despite standard of care treatment, which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study was the proportion of patients achieving a response during weeks 20-32, which was defined as the absence of “phlebotomy eligibility.” To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%.

All patients have completed their participation in the randomized, placebo-controlled portion of the trial evaluating the efficacy and safety of rusfertide plus current treatment versus placebo plus current treatment and are now in the open-label portions of the trial.

## About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to JNJ Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at [www.protagonist-inc.com](https://www.protagonist-inc.com/).

## About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](www.takeda.com).

## Protagonist Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of rusfertide and the timing of rusfertide clinical trial data and regulatory submission. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

## Takeda Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

## Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: <https://www.takeda.com/investors/sec-filings-and-security-reports/> or at [www.sec.gov](www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

## Takeda Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

## Protagonist Investor Relations Contact

**Corey Davis, Ph.D.**

LifeSci Advisors

+1 212 915 2577

<cdavis@lifesciadvisors.com>

## Protagonist Media Contact

**Virginia Amann, Founder/CEO**

ENTENTE Network of Companies

+1 833 500 0061 ext 1

<virginiaamann@ententeinc.com>

## Takeda Media Contacts:

**Japanese Media**

Tsuyoshi Tada

<tsuyoshi.tada@takeda.com>

**U.S. and International Media**

Emy Gruppo

<emy.gruppo@takeda.com>

Explore efficacy and safety results from the Phase 3 VERIFY study evaluating Protagonist and Takeda's rusfertide in patients with polycythemia vera.

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

*	***Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis***
*	***Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau***
*	***Transaction builds upon Takeda’s legacy in the treatment of hematologic cancers and advances company’s global oncology strategy***

**OSAKA, Japan and CAMBRIDGE, Massachusetts, December 3, 2024** – Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/overview/)) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 

Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis (MF). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for very low-, low- and intermediate-risk MDS. MDS and MF are characterized by inadequate blood cell production, often leading to severe anemia that significantly impacts patient health and quality of life. Elritercept targets activin A and B proteins, which are believed to play a crucial role in anemia-associated diseases. In early clinical studies, elritercept has shown promising clinical activity and a manageable safety profile in patients with very low-, low- and intermediate-risk MDS as a monotherapy and in patients with MF in combination with standard of care.

“Elritercept has the potential to make a meaningful difference for patients with blood cancers, one of our key areas of strategic focus,” said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda. “The addition of elritercept further bolsters our oncology pipeline and introduces a potential future growth driver for Takeda. I am excited to further advance the pioneering work begun by the Keros Therapeutics team with the goal of delivering this potential treatment option to patients.” 

Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF. The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk MDS will begin enrollment soon. Takeda plans to evaluate elritercept in these cancers across patient segments and lines of therapy.

“We are excited to partner with Takeda, whose global reach and expertise in oncology and hematology will help unlock elritercept’s potential for patients with MDS and MF,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer at Keros Therapeutics. “With a differentiated mechanism of action targeting a broad range of pathways in blood cell production, elritercept has shown promise for patients who have not responded to standard therapies. This collaboration will accelerate development of elritercept for patients in need and offer new insights into these complex hematologic conditions.”

Under the terms of the agreement, Takeda will receive an exclusive worldwide license to further develop, manufacture and commercialize elritercept in all indications and territories outside of mainland China, Hong Kong and Macau. Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Takeda will provide Keros Therapeutics with an upfront payment of $200 million and potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales. The agreement is subject to customary closing conditions, including completion of antitrust reviews.

## About Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes (MDS) are a group of diverse blood cancers in which the bone marrow fails to produce enough healthy blood cells. MDS is among the most common hematologic malignancies, with approximately 20,000 new cases diagnosed annually in the United States.1 Most people with MDS experience anemia, or low red blood cell counts, which impacts quality of life and mortality.2 75% of people living with MDS have low-risk MDS, with a median survival of approximately three to 10 years.3,4 Many low-risk MDS patients require frequent red blood cell transfusions, which can increase over time and negatively impact quality of life.5 Despite advances, additional therapeutic options are needed to improve quality of life and anemia symptoms for patients with low-risk MDS, particularly those whose disease is ringed sideroblast-negative or who have a high transfusion need.

## About Myelofibrosis (MF)
Myelofibrosis (MF) is a rare and life-threatening blood cancer characterized by the buildup of scar tissue in the bone marrow, which impairs its ability to produce normal blood cells. In the United States, approximately 3,000 new cases of MF are diagnosed each year.6 Patients with MF often experience anemia, enlarged spleen and other symptoms that significantly affect their quality of life. Although standard treatments can reduce spleen size and improve symptoms, they may exacerbate anemia and lead to low platelet counts. 

## About Elritercept
Elritercept is an investigational, potentially best-in-class activin inhibitor, targeting both activin A and activin B proteins, which are believed to play a crucial role in anemia-associated diseases. Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF. The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk MDS will begin enrollment soon. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for this condition. 

## About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](https://www.takeda.com/).

### Media Contacts:

#### Japanese Media

Tsuyoshi Tada

[tsuyoshi.tada@takeda.com](mailto:tsuyoshi.tada@takeda.com)

#### U.S. and International Media

Jennifer Anderson

[jennifer.anderson@takeda.com](mailto:jennifer.anderson@takeda.com)

## Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

## Forward-Looking Statements 
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: [https://www.takeda.com/investors/sec-filings-and-security-reports/](https://www.takeda.com/investors/sec-filings-and-security-reports/) or at [www.sec.gov](https://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

## Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

## References: 
1.	Gorak E, et al. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Adv. 2023 Oct 24;7(20):6120-6129. doi: 10.1182/bloodadvances.2023010061.
2.	Haring Y, et al. MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level. J Clin Med. 2023 Sep 9;12(18):5865. doi: 10.3390/jcm12185865.
3.	de Witte T, et al. Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome: The European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. Haematologica. 2020 Nov 1;105(11):2516-2523. doi: 10.3324/haematol.2020.266817.
4.	Sekeres M, et al. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578.
5.	Wood E, et al. Outpatient transfusions for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):167-174. doi: 10.1182/hematology.2020000103.
6.	Mehta J, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.

Takeda to secure rights to elritercept, a treatment for anemia in hematologic cancers, enhancing their oncology pipeline.

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Discover Takeda's research findings at ASH 2024, highlighting treatments for leukemia, lymphoma, and rare blood disorders.

Takeda to Showcase Latest Research at the 66th American Society of Hematology (ASH) Annual Meeting

## Oncology News



# Oncology Pipeline&#xA;

Discovering and developing innovative therapies to deliver potentially transformative treatments


Science

/science/

Medicines

/medicines/

Patients

/patients/

Investors

https://www.takeda.com/investors/

Partnerships

/partnerships/

Oncology Careers

/about/careers/

## About Takeda Oncology



# Divider Section

**Author: Awny Farajallah, M.D., Chief Medical Officer, Global Oncology Business Unit**

Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. This has led to a stronger focus on survival outcomes, and, in some cancers, many patients are living longer on treatment than ever before thanks to therapeutic developments such as novel targeted therapies and immunotherapy. The improvement in survival rates has created an opportunity – and obligation – to consider factors beyond just survival rates when it comes to the management of the disease.

As we continue to advance treatment options, there has been a growing movement towards prioritizing patient-centered care – considering the individual health status, preferences, values, and goals of patients when making treatment decisions. Balancing clinical outcomes with the real-world experiences of patients can be complex but is necessary to provide the best possible care. 

## Redefining Survival: The Dramatic Impact of Targeted Therapy

Let’s dive a little deeper into one of the reasons we’ve observed such notable improvements in the survival rates for certain cancer types – targeted therapies. Targeted therapies have revolutionized the way some cancers are treated by enabling us to target a genetic mutation that may be driving the cancer. This scientific achievement has dramatically changed the prognosis for certain types of cancers, such as breast and lung.

For example, breast cancer is the second-most common and lethal cancer type in women, and treatment options were previously limited to chemotherapies, radiation, and surgical procedures. For HER2-positive breast cancers specifically, which account for about 20% of all breast cancers, the disease is more aggressive and has a worse prognosis. The development of HER2-targeted drugs has forever changed the treatment approach and patient outcomes. In fact, some treatment combinations for this cancer extend survival to more than 4.5 years, compared to a life expectancy of 1.5 years achieved 14 years ago.1

A similar transformation has occurred in the treatment of non-small cell lung cancer (NSCLC), another widespread cancer that has been historically difficult to treat and was previously treated with chemotherapy, radiotherapy or a combination of both. Over time, we’ve learned that about 70% of patients with NSCLC have a targetable mutation, such as EGFR, BRAF, ALK or KRAS. With improved diagnostic testing, these patients are being matched with treatments that target their cancer at its source. As a result, in recent years, population-level mortality from NSCLC has fallen sharply.2

In addition to longer survival durations, some targeted therapies have also improved upon the toxicity profiles and administration of standard chemotherapies. For example, in a study comparing neoadjuvant targeted therapy versus neoadjuvant chemotherapy in advanced-stage EGFR-mutant NSCLC, the incidence of grade 3/4 adverse events was found to be significantly less in the targeted therapy group compared to the chemotherapy group.3 Many of these targeted therapies are administered orally, providing a more convenient dosing regimen for patients.4-10 

In the 20+ years since the first targeted therapies for cancer were introduced, they have revolutionized the diagnosis and treatment of patients with breast cancer, lung cancer and many other types of cancer, and made the possibility of extending patients’ lives while improving convenience, adherence and safety, a reality.11 

## From Survival to Survivorship 

While the rise in survival rates is an incredible accomplishment that will continue to be built upon as science advances, it has also brought about a paradigm shift in cancer care. With more cancer survivors living longer and more therapeutic options than ever before, there is greater impetus to evolve how we evaluate factors to identify the best treatment for each patient. 

For example, quality of life (QoL) and method of treatment administration are important real-world factors that should be considered in addition to clinical outcomes, as they play a crucial role in the everyday lives and experiences of patients. 

That said, how they are viewed and prioritized can differ by patient. For example, some patients may prioritize convenience and flexibility in treatment administration, while others may be more concerned about potential side effects or the impact of treatment on their ability to work or socialize. Some patients may prefer oral therapies that can be taken at home, while others may be comfortable with intravenous therapies administered in a clinical setting.

Evaluating these factors alongside traditional clinical standards when determining the best possible treatment ensures we are taking not only a patient’s survival into account – but also their quality of survivorship. Survivorship, in the context of cancer, refers to the journey and life experiences patients must navigate following their cancer diagnosis. Despite advancements in care over the past decade, there are still substantial gaps and challenges that need to be addressed to alleviate the short- and long-term effects of treatments – such as fatigue, cognitive problems, and pain – and their impact on an individual’s survivorship and long-term disease management. 

Because real-world factors and their role in survivorship are often not measured in randomized clinical trials, it’s crucial we invest in real-world evidence research and partner with patients and advocacy groups to understand how patients experience and prioritize factors such as location, family type, socioeconomic status, mental health, support systems, and cultural background and how these considerations influence their decisions.

Ultimately, the goal is to provide patients with the best possible opportunity of achieving long-term survival while also maintaining a good quality of life. This requires a collaborative effort between patients, their healthcare providers, and the healthcare industry to ensure that the unique needs and preferences of each patient are considered to improve care. 

## Looking Ahead

While clinical outcomes will continue to be paramount, as treatment options improve, it is imperative that additional factors are considered, and patients are actively involved in the decision-making process. Considering patient preferences on factors like quality of life, treatment feasibility and emotional well-being alongside considerations on clinical efficacy can help optimize outcomes and patient experience. 

By prioritizing an environment of trust, shared decision-making, and open communication, we can empower individuals to actively participate in their treatment journeys and become informed partners in their own care, which has been shown to improve their perception of quality of care and conversations with physicians.12

The future of cancer treatment lies in embracing an approach that considers a complete picture of patient health, recognizing not only survival as a key outcome but also incorporating the patient's overall well-being, or survivorship. By integrating real-world factors into treatment decision-making, prioritizing patient-centered care, and fostering ongoing research, we can collectively transform the cancer survivorship landscape and, hopefully, empower individuals worldwide to lead fulfilling lives beyond their diagnosis.

## References

1. Mendes D, Alves C, Afonso N, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review. Breast Cancer Res 17, 140 (2015). https://doi.org/10.1186/s13058-015-0648-2
2. Howlader H, Forjaz G, Mooradian M, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020;383:640-649. Published 2020 Aug 12. DOI: 10.1056/NEJMoa1916623
3. Chen D, Jin Z, Zhang J, et al. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Surg. 2021;8:715318. Published 2021 Aug 19. doi:10.3389/fsurg.2021.715318
4. Assoun S, Lemiale V, Azoulay E. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med. 2019;45(7):988-997. doi:10.1007/s00134-019-05650-w
5. Atrium Health. Treating Stage IV Lung Cancer With a Pill. Available at: https://atriumhealth.org/dailydose/2018/01/10/treating-stage-iv-lung-cancer-with-a-pill
6. XALKORI Prescribing Information. Pfizer. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=676
7. ZYKADIA Prescribing Information. Novartis. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/zykadia.pdf
8. ALECENSA Prescribing Information. Genentech. Available at: https://www.gene.com/download/pdf/alecensa_prescribing.pdf
9. LORBRENA Prescribing Information. Pfizer. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=11140
10. ALUNBRIG Prescribinig Information. Takeda. Available at: https://www.alunbrig.com/sites/default/files/2022-10/prescribing-information.pdf
11. American Cancer Society. History of Cancer Treatments: Targeted Therapy. Available at: https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-targeted-therapy.html
12. Kehl KL, Landrum MB, Arora NK, et al. Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. JAMA Oncol. 2015;1(1):50–58. doi:10.1001/jamaoncol.2014.112

Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology │ Leadership │ Article

Living is More Than Surviving: Balancing Clinical Outcomes with Patient Impact

In the United States, colorectal cancer (CRC) is the third leading cause of cancer-related deaths, with a projected toll of over 50,000 deaths in 2024. Overall, the lifetime risk of developing CRC is about 1 in 23 for men and 1 in 25 for women.1

When people are diagnosed with later stage or more advanced CRC, it is known as metastatic CRC (mCRC).2 When a cancer metastasizes, it means that cancer cells have spread to other parts of the body.3 When caught early, CRC is often treatable and, in many cases, curable, speaking to the importance of screening and early detection. However, at least 20% of people are diagnosed with CRC in the metastatic stage, and about 50% of people diagnosed with localized CRC will develop metastases over the course of their disease.4,5 After cancer metastasizes, treatment can become much more challenging and as a result, many people experience diminished survival outcomes and quality of life.6

## A Prevalent Cancer, A Lack of Support

While CRC ranks among the most prevalent types of cancers, there are still considerable gaps in care and resources for patients, particularly for those experiencing structural challenges and barriers that impact both treatment access and survival outcomes.

The distribution of CRC and mCRC is not even across U.S. subpopulations; there is a marked difference in incidence among different racial and ethnic groups. For example, Black Americans are about 20% more likely to get CRC and about 40% more likely to die from it than any other racial group in the U.S.7 Additional factors that could impact disease experience with CRC are socioeconomic status, insurance access, geography and environmental exposure, among others.

> There is a wealth of information available around screening and prevention of CRC, but educational resources are sparse by comparison for patients with advanced CRC. While early detection of CRC is the hope, the unfortunate truth is that many people are either diagnosed with advanced CRC or will progress to it over time. Recognizing the challenges and diverse experience of those with mCRC is not widely documented. There is a critical need to develop comprehensive resources to assist the broader community in providing better support, particularly as new treatment options and combinations emerge, offering people more decisions to navigate.
>
> **ASHLEY CALABRESE**
> Associate Director, Policy and Advocacy, US Public Affairs

## A United Purpose to Support Advanced CRC Patients

Joined by a passion to make a difference for advanced CRC patients, Takeda and four leading advocacy organizations are launching a U.S. survey to identify the most pressing needs concerning disease and treatment navigation. Through this collaborative effort, we intend to uncover actionable insights that will help guide the collective development of resources and education to support patients. Our partners include:

**Colorectal Cancer Alliance:** Founded 25 years ago by more than 40 CRC survivors, caregivers and friends, the Alliance advocates for screening, magnifies patient support and accelerates research. It exists to end CRC in our lifetime.

**COLONTOWN:** Founded by a CRC survivor looking to create a disease-specific community, COLONTOWN empowers proactive colorectal cancer patients and caregivers with educational tools and relevant peer-to-peer support.

**BLKHLTH:** BLKHLTH is an Atlanta-based non-profit with a mission to advance the health of Black communities through equity-centered education, advocacy, research and programs.

**Family Reach:** Family Reach is a non-profit that provides non-medical financial support to people facing cancer. They work with patients, providers and community organizations to challenge the systems that force families to choose between their health and their home.

We will be unveiling findings for the survey throughout 2024. To learn more about our partners we are collaborating with, please visit their channels: [Colorectal Cancer Alliance](https://colorectalcancer.org/), [COLONTOWN](https://colontown.org/), [BLKHLTH](https://www.blkhlth.com/) and [Family Reach](https://familyreach.org/).

## References

1. American Cancer Society. Key Statistics for Colorectal Cancer. Available at: <https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html>

2. Memorial Sloan Kettering Cancer Center. Treatment for Metastatic Colon Cancer. Available at: <https://www.mskcc.org/cancer-care/types/colon/treatment/metastases>

3. City of Hope Cancer Treatment Centers. Metastatic Colorectal Cancer (stage 4). Available at: <https://www.cancercenter.com/cancer-types/colorectal-cancer/types/metastatic-colorectal-cancer>

4. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685. doi:10.1001/jama.2021.0106

5. Atreya CE, Yaeger R, Chu E. Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches. Am Soc Clin Oncol Educ Book. 2017;37:246-256. doi:10.1200/EDBK_175679

6. American Cancer Society. Treatment of colon cancer, by stage. Available at: <https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/by-stage-colon.html>

7. American Cancer Society. Colorectal Cancer Rates Higher in African Americans, Rising in Younger People. Available at: <https://www.cancer.org/cancer/latest-news/colorectal-cancer-rates-higher-in-african-americans-rising-in-younger-people.html>

Beyond early detection, how do we bridge the gap in metastatic colorectal cancer care. Learn about Takeda’s partnerships for patient support.

Beyond Early Detection: Bridging the Gaps in Metastatic Colorectal Cancer Support

Technological advances continue to push the boundaries of what's possible. Takeda's Teresa Bitetti discusses how we are leveraging these tools for cancer patients.


 Embracing AI & Emerging Technologies to Advance Cancer Care

**Author: Teresa Bitetti, President, Global Oncology Business Unit**

Many of us have loved ones who have been affected by cancer and understand the immense difficulty of processing a diagnosis and beginning treatment, both for the patient and their support network. Through personal and professional conversations with patients, we also recognize that their challenges often extend far beyond the initial diagnosis.

From financial and job insecurity, to depression and anxiety, to caregiving responsibilities – cancer treatment can be all-consuming. And while developing innovative medicines to treat cancer is at the heart of what we do as a pharmaceutical company, there is a lesser-known part as critical as the medicine – treating the whole patient. It’s this care beyond medicine where we have devoted more support in recent years.

## Mental Health and Well-Being

A cancer diagnosis can take an incredible toll on mental and emotional health, and recognizing changes in mood and behavior are critical during the journey according to the [American Cancer Society](https://www.cancer.org/cancer/managing-cancer/side-effects/emotional-mood-changes.html). Approximately 35% of patients diagnosed with cancer are impacted by a psychiatric disorder, and another 20% experience clinically relevant distressing psychosocial conditions such as demoralization and health anxiety.1 Research has shown that cancer patients receiving mental health support have better outcomes.2 Unfortunately, while mental health support may be a key part of a patient’s treatment journey, it is not always incorporated.3

Fortunately, there are several ways patients can be supported as they navigate the physical and emotional aspects of cancer. I am impressed by the resources that many of our partner patient advocacy organizations such as [CancerCare](https://www.cancercare.org/) provide – including emotional, practical and financial support – to navigate resources and the underlying emotions associated with diagnosis and treatment.

## Life Necessities and Obligations

A cancer diagnosis does not put life on pause. Patients may still need to feed themselves (and also family members), keep a roof over their heads, continue working, among many other aspects of life. Cancer is stressful enough without the added component of determining how to afford life.

Financial hardship impacts one in three patients diagnosed with cancer. And the risks disproportionality affect those who are socioeconomically disadvantaged and working-aged patients.4 The anxiety and stress of affording basic necessities can lead to poorer mental health, which can lead to poorer outcomes, perpetuating a vicious cycle. Fortunately, organizations such as [Family Reach](https://familyreach.org/) provide resources to help patients navigate non-medical expenses. No one should have to make the decision to put treatment on hold to keep food on their table or the lights on at home.

In addition, patients may also be caregivers – to children, to aging parents, to pets – a role that does not disappear at cancer diagnosis. Caregiving can be emotionally and physically taxing even without managing a cancer diagnosis and treatment. Organizations such as [Cancer Support Community](https://www.cancersupportcommunity.org/) offer resources to support dialogue between patient and those in their care as they navigate this journey together.

Cancer treatment is more than medicine. It’s the collaboration and commitment of many stakeholders to ensure that patients receive the care necessary to navigate their journey. At Takeda, I’m proud we partner with patient organizations around the globe – to raise awareness and provide support to help ensure the whole patient is being treated. This is the way we will truly reach our aspiration to cure cancer.

## References:

1. Caruso R, Breitbart W. Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions. *Epidemiol Psychiatr Sci.* 2020;29:e86. doi:10.1017/S2045796019000866

2. Berchuck JE, Meyer CS, Zhang N, et al. Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer. *JAMA Oncol.* 2020;6(7):1055-1062. doi:10.1001/jamaoncol.2020.1466

3. Oncology TL. Provision of mental health care for patients with cancer. *The Lancet Oncology*. 2021;22(9):1199. doi:10.1016/S1470-2045(21)00480-0

4. Smith GL, Lopez-Olivo MA, Advani PG, et al. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. *J Natl Compr Canc Netw.* 2019;17(10):1184-1192. doi:10.6004/jnccn.2019.7305

Hear from Teresa Bitetti, President of the Global Oncology Business Unit, as she discusses how Takeda and its partners are providing cancer care beyond medicine by supporting other areas of patients' lives, such as finances and mental health.

Cancer Treatment is More Than Medicine

# Our Viewpoints



Cancel

You are now leaving Takedaoncology.com and entering a website that is not owned or controlled by Takeda. 

Takeda Oncology makes no representation as to the accuracy of the information contained on websites we do not own or control. Takeda Oncology does not recommend or endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
